Regulus Therapeutics Announces Restructuring of Sanofi and Oxford Loan Agreements

Regulus Therapeutics Announces Restructuring of Sanofi and Oxford Loan Agreements

Los Angeles JOLLA, Calif. , Aug. 31, 2020 /PRNewswire/ — Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical business centered on the development and growth of revolutionary medications focusing on microRNAs, today announced that pursuant to an amendment of Oxford LLC to its term loan agreement, the organization is eligible for up to yet another seven months of great interest just re payments if your Company pays down ten dollars million in loan principal before April 30, 2021 (the “Principal Paydown Event”) utilizing arises from the purchase of materials to, and possible milestones gotten from, Sanofi as described below. Continue reading “Regulus Therapeutics Announces Restructuring of Sanofi and Oxford Loan Agreements”